Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02195986 · ClinicalTrials.gov registry record · Phase 3
A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis
A Phase 3 study, sponsored by Mylan Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 366
- Enrollment target
NCT02195986 is a Phase 3 study that has completed, run by Mylan Pharmaceuticals. The registered enrollment target is 366 participants.
The verdict
NCT02195986, a Phase 3 study, has completed, sponsored by Mylan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 366 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the therapeutic equivalence of Mylan's estradiol vaginal cream to Estrace® cream and superiority of both products to placebo. The protocol describes a randomized, double-blind, multi-dose, placebo-controlled, parallel study of a 7 day treatment.
Interventions
- DRUG Estradiol Vaginal Cream, 0.01%
- DRUG Estrace® 0.01% cream
- DRUG Placebo Vaginal Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2014-06 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02195986
The ClinicalTrials.gov registry entry for NCT02195986 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 366 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan Pharmaceuticals, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Estradiol Vaginal Cream, 0.01% is the first listed.
NCT02195986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02195986 about?
NCT02195986 is a clinical study titled "A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis". The purpose of this study is to determine the therapeutic equivalence of Mylan's estradiol vaginal cream to Estrace® cream and superiority of both products to placebo. The protocol describes a randomized, double-blind, multi-dose, placebo-controlled, parallel study of a 7 day treatment.
What is the current status of trial NCT02195986?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 366 participants. The study started on 2014-06. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02195986?
The interventions under investigation include: Estradiol Vaginal Cream, 0.01% (DRUG), Estrace® 0.01% cream (DRUG), Placebo Vaginal Cream (DRUG).
Who is sponsoring clinical trial NCT02195986?
This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.